Atria Wealth Solutions Inc. Sells 5,851 Shares of Novo Nordisk A/S (NYSE:NVO)

Atria Wealth Solutions Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 13.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,486 shares of the company's stock after selling 5,851 shares during the period. Atria Wealth Solutions Inc.'s holdings in Novo Nordisk A/S were worth $2,567,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL boosted its holdings in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the period. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the period. North Capital Inc. bought a new stake in Novo Nordisk A/S during the first quarter valued at about $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at about $29,000. Finally, Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $33,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Up 4.7%

NYSE NVO opened at $51.06 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The stock's 50 day moving average is $67.14 and its two-hundred day moving average is $71.60. The company has a market capitalization of $227.98 billion, a price-to-earnings ratio of 14.03, a PEG ratio of 1.47 and a beta of 0.63. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be paid a $0.4119 dividend. The ex-dividend date is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's payout ratio is 45.05%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NVO shares. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a research note on Thursday, July 31st. UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $93.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.